Skip to main content

Table 1 The clinical characteristics of EGFR TKI-sensitive and -resistant lung adenocarcinoma patients

From: Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway

   Patient No. EGFR TKI-sensitive EGFR TKI-resistance P
Total No.   28 17 11  
Age, median years   62.68 61.9 63.8 0.396
(range) (59.5–65.8) (58.2–65.7) (57.4–70.2)
Sex      0.315
  Female 16 11 5  
  Male 12 6 6  
Smoking      0.295
  Non-smokers 23 15 8  
  Smokers 5 2 3  
Stage      1
  IV 28 17 11